Which are the causes of Rubinstein-Taybi Syndrome?

Rubinstein-Taybi syndrome (RSTS) is a rare genetic disorder primarily caused by spontaneous mutations in the CREBBP or EP300 genes, which play a critical role in regulating gene expression during early development. These mutations are typically not inherited from parents but occur as new (de novo) genetic events, leading to the characteristic physical features and intellectual disabilities associated with the condition.

What causes Rubinstein-Taybi syndrome at the genetic level?

At its core, Rubinstein-Taybi syndrome is caused by a disruption in the body's "instruction manual" for development. Specifically, the condition is linked to mutations in the CREBBP gene (located on chromosome 16p13.3) in about 50–60% of cases, or the EP300 gene (located on chromosome 22q13.2) in roughly 3–8% of individuals. These genes provide instructions for producing proteins that act as co-activators, helping to "turn on" other genes necessary for normal growth and cognitive development. Think of these proteins as master switches; when one is missing or faulty, the delicate symphony of gene expression required for typical human development is interrupted, resulting in the clinical presentation of Rubinstein-Taybi syndrome.

Is Rubinstein-Taybi syndrome hereditary?

In the vast majority of cases, Rubinstein-Taybi syndrome is not inherited from a parent. It is almost always a sporadic, de novo mutation, meaning it occurs for the first time in the affected individual’s egg or sperm cell, or during early embryonic development. While the recurrence risk for siblings of an affected child is generally very low (less than 1%), there have been extremely rare documented cases of autosomal dominant transmission. Because genetics can be complex, families are encouraged to speak with a clinical geneticist to understand the specific mutation identified in their loved one.

Are there environmental or external triggers for Rubinstein-Taybi syndrome?

There is no evidence to suggest that Rubinstein-Taybi syndrome is caused by environmental factors, maternal health choices, or lifestyle triggers. It is fundamentally a genetic condition. Because the mutation occurs at the molecular level, it cannot be prevented by diet, medication, or external lifestyle changes during pregnancy. It is important for caregivers to understand that nothing done—or not done—before or during pregnancy causes this syndrome.

What is the difference between causes and risk factors?

For Rubinstein-Taybi syndrome, the distinction is clear: the "cause" is the specific genetic mutation in CREBBP or EP300. Unlike common conditions like heart disease or diabetes, there are no known "risk factors" that increase the likelihood of a child being born with this syndrome. It is a random biological event. Our community at DiseaseMaps.org, which includes 232 individuals living with this diagnosis, highlights the importance of focusing on management rather than searching for external causes that do not exist.

What does current research tell us about the etiology of this condition?

Researchers are currently investigating how these specific gene mutations lead to the broad spectrum of symptoms seen in Rubinstein-Taybi syndrome. Current studies focus on:

• Epigenetic mechanisms: Understanding how the loss of CREBBP/EP300 affects the chemical "tags" on DNA that control gene activity.


• Neurodevelopmental pathways: Mapping how these mutations impact the formation and function of synapses in the brain, which contributes to the intellectual disabilities observed in patients.


• Genotype-Phenotype correlations: Examining whether specific types of mutations in CREBBP correlate with more severe or milder physical and cognitive outcomes.

Next steps

• Consult with a clinical geneticist to confirm the diagnosis and discuss the specific gene mutation involved.


• Connect with the 232 members of the Rubinstein-Taybi syndrome community on DiseaseMaps.org to share resources and experiences.


• Schedule routine multidisciplinary evaluations, including cardiology, ophthalmology, and developmental pediatrics, as recommended by specialists.


• Stay updated on clinical trials and research registries via the NIH GARD database.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases (GARD) Information Center: Rubinstein-Taybi syndrome overview.


• Orphanet: Clinical database for rare diseases and orphan drugs (ORPHA791).


• OMIM (Online Mendelian Inheritance in Man): Genetic entries for CREBBP (#180849) and EP300 (#613684).


• Rubinstein-Taybi Syndrome Support Group: International resources for families and clinicians.